A Recap of PropThink’s Top Trades this Week
Most Popular - Our open conference call with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray on Thursday afternoon was a success on a number of fronts – participation, … Continue Reading
Read nowAuthor Archives: Editorial Staff
A PropThink Interview with Tekmira Pharmaceuticals
Long Ideas - On October 3, 2013, PropThink hosted an interview and investor Q&A with Tekmira Pharmaceuticals’ (TKMR) CEO Dr. Mark Murray. A recording and transcript of that … Continue Reading
Read nowBreakout Gains from These Late-Blooming Trades
Most Popular - For those that missed our press release on Friday, PropThink will be hosting a live interview and Q&A with Dr. Mark Murray, CEO of Tekmira Pharmaceuticals (TKMR) (TKM.TO) on Thursday, October 3 … Continue Reading
Read nowSome Weekend Reading: PropThink’s Top Trades and Stories in Healthcare
Long Ideas - Shares of ViroPharma soared by 25% on Friday as Bloomberg reported that the drug developer has hired Goldman Sachs to explore takeover offers following interest … Continue Reading
Read nowPropThink’s Lead Stories in Biotech from the Labor Day Week
Long Ideas - The Amarin (AMRN) run-up has been in full swing this month. Recall that in June, Mr. King outlined why he expected a robust run-up into the FDA … Continue Reading
Read nowFollowup: Speculating on Isis with APOCIIIRx Data this Weekend
Long Ideas - Editor’s note: This trade was sent to PropThink Premium members on Friday, August 30. Purchased Sept 28 calls were good for more than 70% by the close … Continue Reading
Read nowEven With Volatility in the Macro, We’re Finding Opportunities; PropThink’s Weekly Rundown
Long Ideas - Orexigen (OREX) is getting interesting again. The obesity drug developer – perhaps Goldilocks’ perfect bowl after two previous attempts (ARNA, VVUS) – iterated this week that … Continue Reading
Read now